HDAC9 and pulmonary arterial hypertension: In patients with PAH, it is crucial to determine the type of RV function and remodeling before using general HDAC inhibitors because they may lead to issues such as thrombocytopenia, pulmonary embolism, and electrocardiographic abnormalities in patients with lymphoma.